Home / Private raises / Vesalius Longevity Labs Inc.
Vesalius Longevity Labs Inc.
Pharmaceuticals · Vancouver, British Columbia, Canada · $36.6M sold across 2 offerings
Form D filings (2)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-11-18 | D (new) | $6.5M | $13.5M | 9 | 506(b) | Equity, Options/warrants, Security to be acquired | Nov 6 | SEC ↗ |
| 2026-11-03 | D (new) | $30.1M | $30.1M | 62 | 506(b) | Equity | Oct 28 | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Issuer
| Industry | Pharmaceuticals |
| Located | Vancouver, British Columbia, Canada |
| Entity | Corporation |
| Incorporated | British Columbia, Canada |
| SEC CIK | 2131865 |
People named in the latest filing
| Name | Role |
|---|---|
| Christopher Cooper | Chief Financial Officer |
| Kevin Serre | Director |
| Robert McCue | Director |
| Joel Leonoff | Director |
| Kevin Mayer | Director |
| Lee Applbaum | Director |
| David Adelman | Director |
| Timmi Stump | Executive Officer |
| Pradeep Albert | Chief Executive Officer |
| James McRoberts | Director |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
